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Extra-renal production of 24,25-dihydroxyvitamin D in chronic renal
failure during 25 hydroxyvitamin D3 therapy. To assess whether or not
production of 24,25-dihydroxyvitamin D [24,25-(OH)2DJ can occur in
patients with renal failure, we administered 25-OHD3 (100 big/day) to
eight patients undergoing chronic hemodialysis, six of whom had intact
kidneys (CRF) and two who were anephric. Prior to 25-OHD3 adminis-
tration, serum 24,25-(OH)2D was undetectable (UD), (<0.3 ng/ml) in all
subjects except for one patient with CRF and one anephric subject in
whom concentrations of 24,25-(OH)2D were 0.5 ng/ml and 1.5 ng/ml,
respectively. The administration of 25-OHD3 (100 jrg/day) for 8 weeks
to six CRF and two anephric patients produced significant increases in
serum 24,25-(OH)2D concentration, from UD to 2.9 0.5 SEM ng/ml (P
< 0.0025) in CRF, and from 0.9 0.4 ng/mt to 2.6 0.8 ng/ml (P <
0.005) in the anephric group. Serum 24,25-(OH)2D concentration was
found to be correlated significantly with serum 25-OHD concentration
(r = 0.93, P < 0.01). Serum l,25-(OH)2D did not change in anephric
subjects but significantly increased in patients with CRF (9 3 to 14
3 pg/mI, P < 0.05). Additional studies in seven normal subjects and
seven anephric patients who received I ,25-(OH)2D (2 .tglday) for 8 days
disclosed a significant increase in serum 24,25-(OH)2D in normals (2.4
0.2 ng/ml to 3.3 0.3 ng/ml, P < 0.05) but not in the anephric
humans. The data suggest that there is an impaired ability to bioproduce
24,25-(OH)2D in anephric humans or in CRF, but that sufficient
provision of the substrate (25-OHD3) may result in the extra-renal
production of 24,25-(OH)2D. The extra-renal production of 24,25-
(OH)2D does not appear to be regulated in a comparable fashion to that
of the renal enzyme, since I,25-(OH)2D administration failed to raise
24,25-(OH)2D concentration in anephric subjects. Despite low serum
I ,25-(OH)2D concentrations in patients with CRF, 25-OHD therapy
may also raise 1,25-(OH)2D levels in some patients, suggesting the
presence of residual la-hydroxylase activity.
La production extra-rénale de 24,25-dihydroxyvitamine dans l'insuffi-
sance rénale chronique pendant un traitement par Ia 25-hydroxyvitamine
D3. Afin de determiner si Ia production de 24,25-dihydroxyvitamine D
[24,25-(OH)2D1 peut avoir lieu chez des malades en insuffisance rénale
chronique, nous avons administré de Ia 25-OHD1 (100 pg/jour) a huit
malades en hCmodialyse chronique, dont six avaient des reins intacts
(CRF) et deux étaient anéphriques. Avant l'administration de 25-OHD,
Ia 24,25-(OH)2D sérique était indétectable (UD), (<0,3 ng/ml) chez tous
les sujets sauf un malade CRF et un sujet anephrique chez lesquels les
concentrations de 24,25-(OH)2D étaient de 0,5 ng/ml et de 1,5 ng/ml,
respectivement. L'administration de 25-OHD1 (100 pg/jour) pendant 6
semaines a six malades CRF et deux anephriques a entrainé des
augmentations signilicatives de La concentration sérique de 24,25-
(OH)2D, passant de UD a 2,9 0,5 SEM ng/ml (P < 0,0025) chez les
CRF et de 0,9 0,4 ng/ml a 2,6 0,8 ng/ml (P < 0,005) chez Ic groupe
anéphrique. La concentration sérique de 24,25-(OH)2D a été trouvée
signilicativement corrélée a Ia concentration sérique de 25-OHD (r =
0,93, P < 0,01). La l,25-(OH)2D sérique n'a pas change chez les sujets
anephriques, mais s'est significativement élevée chez les malades CRF
(de 9 3 a 14 3 pg/mI, P < 0,05). Des etudes supplémentaires chez
sept sujets normaux et sept malades anephriques ayant recu de Ia 1,25-
(OH)2D (2 pg/jour) pendant huit jours ont révélé une augmentation
significative de la 24,25-(OH)2D sCrique chez les normaux (2,4 0,2 ng/
ml a 3,3 0,3 ng/mI, P < 0,05) mais pas chez les anephriques. Ces
données suggèrent qy'il y a une capacité altérée a produire de Ia 24,25-
(OH)2D chez des hommes anéphriques ou CRF, mais qu'un apport
suffisant du substrat (25-OHD3) peut entrainer une production extra-
rénale de 24,25-(OH)2D. La production extra-rénale de 24,25-(OH)0D
ne parait pas soumise a la méme regulation que l'enzyme rénale,
puisque l'administration de 1 ,25-(OH)2D n'a pas permis d'augmenter Ia
concentration de 24,25-(OH)2D chez des sujets anephriques. Malgré de
faibles concentrations de 1,25-(OH)2D chez les malades avec CRF, Ic
traitement par Ia 25-OHD3 peut également élever Ic niveau de 1,25-
(OH)2D chez certains malades, suggérant Ia presence d'une activité irs-
hydroxylase résiduelle.
The kidney has been shown to be an important site of vitamin
D metabolism. Bioproduction of I ,25-dihydroxyvitamin D
[l,25-(OH)2D], the physiologically active form of vitamin D, is
known to occur principally in renal mitochondria [I] and is
regulated tightly by the calcium and phosphorus status [2, 3].
Another renal metabolite of vitamin D whose bioproduction
appears to be regulated is 24,25-dihydroxyvitamin D [24,25-
(OH)2D] [41. The activities of the 25-hydroxyvitamin D (25-
OHD) la- and 24-hydroxylase, the enzymes responsible for the
production of la,25-(OH)2D and 24,25-(OH)2D, respectively,
have been reported to be reciprocal. Under conditions of
vitamin D depletion 25-OHD is preferentially metabolized to
l,25-(OH)2D but during vitamin D replete states 24,25-(OH)2D
is bioproduced. Thus, the renal 24-hydroxylase is stimulated by
l,25-(OH)2D or normal serum calcium but suppressed by para-
thyroid hormone (PTH). These reciprocal changes in enzyme
activity have been demonstrated both in vivo [4, 5] and in vitro
[6, 7].
Although reports have demonstrated the existence of extra-
renal sites of l,25-(OH)2D production in placenta [8, 9] and
bone cells [101, still to be resolved is whether or not 24,25-
(OH)2D is exclusively a product of the kidney. Recent studies
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Jersey. 25-OHD3-26,23 lactone was generously provided by Dr.
J. Napoli, Department of Biochemistry, University of Texas,
Southwestern Medical School, Dallas, Texas. All radioactive
vitamin D metabolites used in the respective assays and for
column chromatography standardization were purchased from
Amersham-Searle, Arlington Heights, Illinois.
The procedure for the extraction of the vitamin D metabolites
was identical to that described by Bishop et al [23]. The dried
______________________
extract was then applied to a 1 x 10 cm column of Sephadex
LH-20 (Sigma Chemical Co., St. Louis, Missouri) suspended in
a chloroform-hexane (60:40) solvent system and developed in
the same solvent system. The initial 3 ml were discarded and
the next 6 ml collected as 25-OHD. The next 30 ml contained
both 24,25-(OH)2D and l,25-(OH)2D. Final separation and
purification of the vitamin D metabolites were performed on a
Glenco high pressure liquid chromatograph (Glenco Instru-
ments, Houston, Texas) utilizing a Supelcosil 150 x 4.5 mm
column (Supelco, Bellefonte, Pennsylvania). 25-OHD was pun-
fled with a 5% 2-propanol in hexane solvent system. 24,25-
(OH)2D was separated from 1 ,25-(OH)2D, and final purification
of both metabolites was accomplished with an 8% 2-propanol in
hexane solvent system. Final yields for each metabolite aver-
aged 60%.
Serum 25-OHD and 24,25-(OH)2D were assayed separately
utilizing the rat serum binding protein system [24]. The sensitiv-
ity of each assay is 0.3 ng/ml of serum when using a 2-mi serum
sample and performing assays in triplicate.
Our described purification scheme for 24,25-(OH)2D used for
each patient's serum in this study does not resolve this metabo-
lite from 25-OHD1-26,23 lactone, (Fig. IA) a vitamin D metabo-
lite that can compete approximately five times better than
24,25-(OH)2D in the binding assay [181. However, a 3% 2-
propanol in hexane solvent system was found to effectively
separate 25-OHD3-26,23 lactone from 24,25-(OH)2D1. Utilizing
this solvent system, we failed to observe any measurable
quantity of 25-OHD3-26,23 lactone in a pooled 5-mi serum
sample from either the two anephric subjects or two CRF
patients after 8 weeks of 25-OHD3 therapy (Fig. IB). However,
significant concentrations of 24,25-(OH)2D were present in
these pooled serums suggesting that only 24,25-(OH)2D was
being bioproduced in each individual after 25-OHD1 administra-
tion and not 25-OHD3-26,23 lactone.
Assay of sera for I ,25-(OH)2D was performed in triplicate on
each sample as previously described [25] except that separation
of free sterol from bound was accomplished with hydroxylapa-
tite [26]. The limit of detection with this assay utilizing radioac-
tive 1 ,25-(OH)2D at a specific activity of 110 Ci/mmole is 8 pg/
ml of serum when using a 2-ml serum sample with 60% recovery
during purification. No attempt was made to determine the
concentration of the vitamin D2 forms of each metabolite. Since
our chromatographic procedures were standardized to collect
only the D3 form of the vitamin, we do not know if the D2 form
of each metabolite was also being measured. Thus, the values
obtained in this study represent total vitamin D concentrations
and are thus designated without a subscript.
Serum immunoreactive parathyroid hormone (iPTH) was
determined using antiserum (Diagnostic Systems Laboratories,
Webster, Texas) which recognized principally the carboxyterm-
inus to the PTH molecule. Bovine PTH was used as the tracer,
and human PTH (from culture of human parathyroid tissue
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Fig. 1. A Elution of 25-OHD3-26,23-lactone, 24,25-(OH)2D3, and 1,25-
(OH)2D3 from an HPLC Supelcosil column developed in 8:92 isopropa-
nol:hexane with aflow rate of 1.0 mI/mm. B Elation of25-OHD1-26,23-
lactone and 24,25-(OH)2D3 from an HPLC Supelcosil column devel-
oped in 3:97 isopropanol: hexane with a flow rate of 1.0 mI/mm. The
solid line represents the elution profile of standards while the dotted line
represents the elution of material found to compete in the 24,25-(OH)2D
assay. This material was obtained from an anephric serum pooi during
25-OHD3 therapy.
have demonstrated low [11] to normal [12, 131 concentrations of
24,25-(OH)2D in anephric human serum, presumably a reflec-
tion of extra-renal 25-OHD 24-hydroxylase activity [14, 151. In
contrast to these reports, Taylor et al [161 and Taylor [17] failed
to detect 24,25-(OH)2D in serum of anephric man with normal
or above normal 25-OHD concentrations. These results have
been confirmed recently by Horst et al [181. However, studies
in anephric pigs [18], rats [191, and most recently humans [20]
have demonstrated extra-renal production of 24,25-(OH)2D3
when serum 25-OHD3 concentration is elevated by administra-
tion of this vitamin D metabolite or its parent form.
To address the issue of whether or not extra-renal production
of 24,25-(OH)2D can occur in severe renal failure, we have
measured the serum concentrations of 24,25-(OH)2D, 25-OHD,
and 1 ,25-(OH)2D in anephric patients and patients with chronic
renal failure with intact kidneys (CRF) undergoing dialysis after
8 weeks of oral 25-OHD3 therapy (100 1Lg/day). Seven addition-
al anephric subjects and seven normal volunteers received 1,25-
(OH)2D3 to determine whether extra-renal production of 24,25-
(OH)2D is regulated in a manner similar to the renal enzyme.
This information could be of importance in the treatment and
prevention of renal osteodystrophy since 24,25-(OH)2D has
been implicated in bone formation and mineralization [21, 22].
Sterols and assays. 25-OHD3 and 1c,25-(OH)2D3 were gifts
from the Upjohn Company, Kalamazoo, Michigan. 24,25-
(OH)2D3 was a gift from Hoffmann-LaRoche, Nutley, New
Methods
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Table 1. Basal vitamin D metabolite concentrations in chronic hemodialysis patientsa
Basal
25-OHD3
(100 ,.tg/d
for 8 weeks)
25-OHD 24,25(OH)2Dd I ,25-(OH)2D
ng/ml ng/ml pg/mi
25-OHD 24,25(OH)2Da l,25(OH)2Db iPTH Serum Ca Serum P
nglml nglml pg/mi dEq/ml mg/di mg/di
a When 24,25-(OH)2D values were undetectable, the limit of sensitivity of the assay (0.3 ng) was used for calculation purposes.
When 1 ,25-(OH)2D values were undetectable, the limit of sensitivity of the assay (8 pg) was used for calculation purposes.
Values were significantly different from the basal value as calculated by paired t test at
P < 0.05;
d P < 0.025;
P < 0.005;f <0.0025.
kindly provided by Dr. B. Roos, Case Western Reserve Univer-
sity, Cleveland, Ohio) was used as the standard. This assay
provided detectable values in more than 95% of normal subjects
tested as previously demonstrated [27]. Although this assay
demonstrated elevated iPTH values for all patients with CRF,
this may not be a true measure of biologically active hormone
concentration. This is based upon observations which demon-
strate the predominance of C-region iPTH fragments (presumed
to be biologically inert) relative to intact PTH in CRF serum.
Study protocol. Six patients with stable chronic renal failure
(CRF) (creatinine clearance <2 mi/mm) who were undergoing
hemodialysis (HD) and two anephric subjects undergoing HD
also underwent oral 25-OHD3 therapy (100 .tg/day) for a period
of 8 weeks. Patients were selected randomly from those who
had not received any vitamin D supplementation. Serum was
obtained at 2-week intervals for measurement of vitamin D
metabolites, iPTH, serum calcium and phosphorus.
Seven normal subjects and seven additional anephric subjects
were assessed prior to and following 8 days of oral 1,25-
(OH)2D3 therapy (2 pg/day in four divided doses). Serum was
obtained for analysis as described above. All patients were on
their usual diets during the study period, and none had been
treated with vitamin D prior to the study. Results are expressed
as the mean SEM. Significance was determined by use of
Student's t test for between group comparisons and the paired I
test for within group comparisons.
Results
Basal vitamin D metabolite concentrations. Prior to the
initiation of 25-OHD3 administration, no 24,25-(OH)2D was
detected in the serum of eight of nine anephric subjects or in
five of six patients with CRF. Values of 1.5 and 0.5 ng/ml were
disclosed in an anephric subject and in one patient with CRF,
respectively. Although serum 25-OHD levels were significantly
lower than the normal mean concentration, the values were
within the normal range (16 2 SEM ng/ml) in CRF and for the
nine anephric subjects (14 1 nglml) (Table 1). As expected,
serum l,25-(OH)2D was reduced significantly for patients with
CRF (9 3 pg!ml, P <0.001) and for the anephric subjects (8
1 pg/ml, P <0.001) as compared to the normal value of 34 2
pglml.
Effect of 25-OHD3 administration in anephric humans and in
CRF. Administration of 25-OHD3 (100 pg/day) for 8 weeks
resulted in a marked elevation of serum 25-OHD concentration
in both anephric subjects and for the six patients with CRF
(Table 2). By 8 weeks 25-OHD concentrations reached a mean
Group
Normal range (25) 24 3 2.5 0.4
CRF; intact kidneys (6) 16 2b 0.3 0.P'
Anephric (9) 14 lb 0.4 Q3b
34 2
9 3
8 1
a Numbers in parentheses represent the number of patients in each group. All values are mean SEM.
Values were significantly different from the normal mean value at: b P < 0.005 and P < 0.001.
When 24,25-(OH)2D values were undetectable, the limit of sensitivity of the assay (0.3 ng) was used for calculation purposes.
When I ,25-(OH)2D values were undetectable, the limit of sensitivity of the assay (8 pg) was used for calculation purposes.
Table 2. Effect of 25-OHD3 administration in chronic hemodialysis patients
TreatmentGroup
Normal subjects
(N = 25)
CRF, intact
kidneys (N = 6)
Anephric patients
(N =2)
24— 3
16± 298 be
12± 3
82 28e
2.5 0.4
0.3 0.1
2.9 0.5
0.9 0.4
2.6 0.8e
Basal
25-OHD3 (100
g/d for 8
weeks)
34 2
9±314 3
8±1
8±1
< 36 8.5 — 10.5 2.5 — 4.5
182 39 9.2 0.3 3.3 0.7
188 68 9.8 0.3c 4.5 0.5
296 45 7.6 0.4 4.2 0.8
254 31 8.1 0.1 7.4 2.9
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value of 98 10 nglml in CRF and 82 28 nglml for the two
anephric subjects. Both mean values were significantly different
(P < 0.005) from the pre-treatment serum concentration of 25-
OHD. An increase in the serum concentration of 24,25-(OH)2D
occurred, commensurate with the rise in serum 25-OHD. This
was true for patients with CRF (mean value, 2.9 0.5 ng/ml, P
<0.0025 from pre-treatment) and for anephric subjects (mean
value, 2.6 0.8, P < 0.005 from pre-treatment; Table 2).
Furthermore, the increase in serum 24,25-(OH)2D concentra-
tion was correlated positively with the increase in serum 25-
OHD concentration for the entire 8-week period (r 0.93, P <
0.01; Fig. 2).
Although administration of 25-OHD3 failed to raise serum
1 ,25-(OH)2D levels in anephric patients, a significant increase
did occur for patients with CRF and intact kidneys (9 3 to 14
3 pg/mI, P < 0.05; Table 2). Three CRF patients demonstrat-
ed serum 1 ,25-(OH)2D concentrations within the normal range
at 6 weeks of therapy (Fig. 3), but the remaining three CRF
subjects showed no significant elevation in 1 ,25-(OH)2D.
During 25-OHD3 administration there were no significant
changes in iPTH or serum P in chronic HD patients with intact
kidneys. The two anephric subjects demonstrated a fall in iPTH
and a significant increase in serum phosphorous (Table 2).
Serum calcium was increased significantly (P < 0.025) by 8
weeks of 25-OHD3 administration in HD patients with CRF and
intact kidneys. Hypercalcemia was evident in two of these
latter CRF subjects at 8 weeks of 25-OHD3 therapy. Discon-
tinuance of the drug corrected the hypercalcemia.
Effect of1,25-(OH)2D3 administration in normal and aneph-
nc humans. The results of 1,25-(OH)2D3 administration in
normal and anephric humans is summarized in Table 3. Two
micrograms per day of 1 ,25-(OH)2D3 produced a significant
increase in the serum concentration of 1 ,25-(OH)2D in both
groups. Serum 25-OHD levels remained unchanged while the
mean serum 24,25-(OH)2D concentration significantly in-
I
Time, weeks of 25-QH-03 therapy
Fig. 3. Serum concentration of 1,25-(OH)2D in six hemodialysis sub-jects with CRF and intact kidneys and two anephric subjects on
hemodialysis who received 25-OHD3 for8 weeks (100 sgId). Each line
represents a study in a single patient and is depicted by CRF (•—I)
and anephrics (0—0). The limit of sensitivity for the assay is represent-
ed by the shaded region.
creased in normal subjects (2.4 0.2 nglml to 3.3 0.3, P <
0.05). Seven anephric subjects failed to demonstrate an increase
in the serum concentration of 24,25-(OH)2D, and all values
remained undetectable.
Serum iPTH decreased in both patient groups during 1,25-
(OH)2D3 administration. This change was significant for the
anephric subjects (Table 3). There were no significant changes
in serum calcium or phosphorus.
Discussion
Our results have demonstrated very low to nonietectab1e
levels of 24,25-(OH)2D in serum from anephric patients under-
going hemodialysis as well as HD patients with intact kidneys.
This finding agrees with previous reports supporting a lack of
measurable 24,25-(OH)2D in serum of anephric humans [16—18].
One subject with CRF and one anephric patient had relatively
normal levels of 24,25-(OH)2D. Because our assay does not
discriminate between the D2 and D3 forms of the vitamin, we
were unable to determine if these normal values were due to
prior vitamin D2 therapy.
The major purpose of this study was to assess whether
patients with renal failure on dialysis with or without intact
kidneys have the capacity to produce 24,25-(OH)2D. In aneph-
nc people extra-renal tissues such as the intestine [14] or bone
could be such a site of production [15]. When superphysiologi-
cal serum 25-OHD concentrations were achieved by exogenous
25-OHD3, a significant (and qualitatively similar) increase in the
serum concentration of 24,25-(OH)2D was found in all six
patients with CRF and in both anephric subjects. The mean
increase in serum 24,25-(OH)2D concentration correlated posi-
tively with the mean increase in serum 25-OHD concentration.
These data are in contrast to the findings of Taylor et al [16]
and Taylor 117] who found undetectable values for 24,25-
I = 0.93 1P<0.01
20 40 60 80 100 120 140 160
Serum 25-OHD,ng/mI
Fig. 2. Correlation of serum 24,25-(OH)2D concentration with serum 25-
OHD concentration during an 8-week administration of 25-OHD3 (100
g/d) in six hemodialysis patients with CRF and intact kidneys (N = 6)
and two anephric subjects on chronic hemodialysis (N = 2). Each point
corresponds to the basal value and reevaluation at 2, 4, 6, and 8 weeks
of 25-OHD3 administration. Values shown are mean SEM for all eight
subjects. Regression analysis yielded a significant correlation (P <
0.01).
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Table 3. Effect of 1 ,25-(OH)2D3 administration in normal and anephric humans
Group Treatment
25-OHD
ng/ml
24,25(OH)2Da
ng/ml
1,25(OH)2Db
pg/mi
iPTH
piEqimi
Serum Ca
mg/dl
Serum P
mg/dl
Normals Basal 34 6 2.4 0.2 26 4 30 2 9.5 0.1 3.3 0.3(N 7) l,25-(OH)2D3 32 6 3.3 0.3w 46 5d 28 2 9.5 0.1 3.8 0.4
(2 1tg/d for 8 days)
Anephric Basal 14 3 0.3 0.1 8 1 254 19 9.4 0.3 5.9 0.5
patients l,25-(OH)2D3 13 2 0.3 0.1 89 J5a 226 31c 9.8 0.4 6.4 0.5
(N = 7) (2 gId for 8 days)
a When 24,25-(OH)2D values were undetectable, the limit of sensitivity of the assay (0.3 ng) was used for calculation purposes.
b When 1 ,25-(OH)2D values were undetectable, the limit of sensitivity of the assay (8 pg) was used for calculation purposes.
Significantly different from the basal value as calculated by paired t test at
P < 0.05.
d P < 0.005.
a P < 0.001.
(OH)2D in anephric subjects who had been dosed with vitamin
D3 or 25-OHD3. This discrepancy might be explained by the
relatively short (4 days) period of 25-OHD3 administration in
the study of Taylor et al [16]. Using a comparable dose of 25-
OHD3 (100 1iglday), we observed that not all patients demon-
strated increases in serum 24,25-(OH)2D by 2 weeks of therapy.
In fact, 4 weeks or longer of daily 25-OHD3 administration was
required for all patients to achieve increased serum 24,25-
(OH)2D concentrations. This observation may indicate that the
extra-renal 25-OHD-24-hydroxylase may have a higher Km than
that for the renal enzyme.
Alternatively, our isolation and purification scheme for 24,25-
(OH)2D does not separate 25-OHD3-26,23 lactone from 24,25-
(OH)2D. Since this metabolite has been shown to compete with
24,25-(OH)2D in the rat serum binding protein assay [18], the
possiblity is raised that our assay may be detecting this metabo-
lite also. This is unlikely since production of 25-OHD3-26,23
lactone requires intact renal function [28, 29]. Furthermore, we
were unable to detect any 25-OHD3-26,23 lactone in the serum
from CRF patients and anephric subjects after 8 weeks of 25-
OHD3 administration when the putative 25-OHD3-26,23 lactone
peak was separated by high pressure liquid chromatography
using a 3% 2-propanol in hexane solvent system, despite
measureable levels of 24,25-(OH)2D. No attempts were made to
determine if 25,26-(OH)2D, another metabolite which can com-
pete in the 24,25-(OH)2D assay [11], was present in the serum of
CRF and anephric subjects before and following 25-OHD3
administration. Although previous studies have demonstrated a
lack of 25 ,26-(OH)2D2 in anephric serum [18], others have
demonstrated the capacity of anephrics to bioproduce 25,26-
(OH)2D [11, 13]. However, our purification step with high
pressure liquid chromatography should resolve 24,25-(OH)2D
from 25,26-(OH)2D as shown by others [301 using a similar
solvent system. Thus, it would appear that the metabolite in
question is indeed 24,25-(OH)2D.
An additional finding in this study was the apparent ability of
some HD patients with intact kidneys and CRF to bioproduce
1 ,25-(OH)2D when sufficient substrate (25-OHD3) is provided.
It is not known whether this lcs-hydroxylation is of renal or
extra-renal origin or a combination of both. Although a previous
report suggests the presence of extra-renal la-hydroxylase
activity in humans [20], our anephric subjects had undetectable
values of l,25-(OH)2D in the basal state and during 25-OHD3
administration and does not support a role for extra-renal I a-
hydroxylase activity under these conditions. Studies in addi-
tional anephric subjects will be required to address this issue.
These observations would also suggest that residual renal 24-
hydroxylase activity might be present in patients with CRF with
intact kidneys and that the increase in serum 24,25-(OH)2D
concentration observed in this study might be due to the renal
enzyme. However, the magnitude of increase in serum 24,25-
(OH)2D for patients with CRF as compared to the anephric
subjects was comparable, indicating similar 24-hydroxylase
activities. Furthermore, the elevated iPTH levels observed in
these patients would promote the stimulation of renal 1 -hydrox-
ylase activity and not 24-hydroxylase. These considerations
support the notion that the observed increases in serum 24,25-
(OH)2D in CRF subjects after 25-OHD3 administration are a
result of extra-renal 24-hydroxylation.
The nature and site of this hypothesized extra-renal 24-
hydroxylation is unknown. It does not appear to be identical to
the renal enzyme with regard to regulation since we failed to
detect an increase in serum 24,25-(OH)2D in anephric subjects
who received 1,25-(OH)2D. This regimen was shown to signifi-
cantly increase 24,25-(OH)2D in normal subjects in this study
and by others [17]. Although comparable studies in CRF
patients were not performed in this investigation, similar find-
ings to those observed in anephrics would provide further
support for the hypothesis that the extra-renal enzyme is not
regulated tightly. Furthermore, it still remains to be determined
whether or not raising serum 24,25-(OH)2D concentrations in
anephric patients by giving exogenous 25-OHD3 offers any
distinct advantage to I ,25-(OH)2D3 in the management of renal
osteodystrophy.
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